<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD11920000_1</Organism_ID>
  <Organism>HIV-1</Organism>
  <Organism_Latin>Human immunodeficiency virus type 1 group M subtype B</Organism_Latin>
  <UniProt_ID>P0C6F2</UniProt_ID>
  <Seq_Length>1435</Seq_Length>
  <Molecule_Weight>162076</Molecule_Weight>
  <Function_Summary>Gag-Pol polyprotein: Mediates, with Gag polyrotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shutt off translation.Matrix protein p17: Targets the polyprotein to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. Matrix protein is part of the pre-integration complex. Implicated in the release from host cell mediated by Vpu. Binds to RNA.Capsid protein p24: Forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry (By similarity). Host restriction factors such as TRIM5-alpha or TRIMCyp bind retroviral capsids and cause premature capsid disassembly, leading to blocks in reverse transcription. Capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species. Host PIN1 apparently facilitates the virion uncoating. On the other hand, interactions with PDZD8 or CYPA stabilize the capsid.Nucleocapsid protein p7: Encapsulates and protects viral dimeric unspliced genomic RNA (gRNA). Binds these RNAs through its zinc fingers. Acts as a nucleic acid chaperone which is involved in rearangement of nucleic acid secondary structure during gRNA retrotranscription. Also facilitates template switch leading to recombination. As part of the polyprotein, participates to gRNA dimerization, packaging, tRNA incorporation and virion assembly.Protease: Aspartyl protease that mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity).Reverse transcriptase/ribonuclease H: Multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends.Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre-integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.</Function_Summary>
  <Catalytic_Mechanism>Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.@@&lt;text evidence=6&gt;Endohydrolysis of RNA in RNA/DNA hybrids. Three different cleavage modes: 1. sequence-specific internal cleavage of RNA. Human immunodeficiency virus type 1 and Moloney murine leukemia virus enzymes prefer to cleave the RNA strand one nucleotide away from the RNA-DNA junction. 2. RNA 5'-end directed cleavage 13-19 nucleotides from the RNA end. 3. DNA 3'-end directed cleavage 15-20 nucleotides away from the primer terminus.@@&lt;text evidence=6&gt;3'-end directed exonucleolytic cleavage of viral RNA-DNA hybrid.@@&lt;text evidence=14&gt;Deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1).</Catalytic_Mechanism>
  <Pfam_ID>PF00540:Gag_p17@@PF00607:Gag_p24@@PF00552:IN_DBD_C@@PF02022:Integrase_Zn@@PF00075:RNase_H@@PF00665:rve@@PF00077:RVP@@PF00078:RVT_1@@PF06815:RVT_connect@@PF06817:RVT_thumb@@PF00098:zf-CCHC</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>50</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>p66 RT</Alias>
      <Alias>Integrase</Alias>
      <Alias>Reverse transcriptase/ribonuclease H</Alias>
      <Alias>SP1</Alias>
      <Alias>CA</Alias>
      <Alias>Capsid protein p24</Alias>
      <Alias>Pr160Gag-Pol</Alias>
      <Alias>p6-pol</Alias>
      <Alias>MA</Alias>
      <Alias>Protease</Alias>
      <Alias>IN</Alias>
      <Alias>Retropepsin</Alias>
      <Alias>p15</Alias>
      <Alias>Exoribonuclease H</Alias>
      <Alias>Transframe peptide</Alias>
      <Alias>p6*</Alias>
      <Alias>Nucleocapsid protein p7</Alias>
      <Alias>p51 RT</Alias>
      <Alias>PR</Alias>
      <Alias>NC</Alias>
      <Alias>p2</Alias>
      <Alias>TF</Alias>
      <Alias>Matrix protein p17</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1). Catalyzes RNA-template-directed extension of the 3'- end of a DNA strand by one deoxynucleotide at a time.</Detail>
      <Keyword>RNA-directed DNA polymerase activity</Keyword>
      <Ontology_ID>GO:0003964</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an RNA molecule or a portion thereof.</Detail>
      <Keyword>RNA binding</Keyword>
      <Ontology_ID>GO:0003723</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of ester linkages within nucleic acids.</Detail>
      <Keyword>Nuclease activity</Keyword>
      <Ontology_ID>GO:0004518</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a nucleotidyl group to a reactant.</Detail>
      <Keyword>Nucleotidyltransferase activity</Keyword>
      <Ontology_ID>GO:0016779</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which a water molecule bound by the side chains of aspartic residues at the active center acts as a nucleophile.</Detail>
      <Keyword>Aspartic-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004190</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>The action of a molecule that contributes to the structural integrity of a complex or assembly within or outside a cell.</Detail>
      <Keyword>Structural molecule activity</Keyword>
      <Ontology_ID>GO:0005198</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic.</Detail>
      <Keyword>Catalytic activity</Keyword>
      <Ontology_ID>GO:0003824</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the exonucleolytic cleavage of RNA to 5'-phosphomonoester oligonucleotides in both 5' to 3' and 3' to 5' directions.</Detail>
      <Keyword>Exoribonuclease H activity</Keyword>
      <Ontology_ID>GO:0004533</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of ester linkages within nucleic acids by creating internal breaks.</Detail>
      <Keyword>Endonuclease activity</Keyword>
      <Ontology_ID>GO:0004519</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the endonucleolytic cleavage of RNA in RNA-DNA hybrids to 5'-phosphomonoesters.</Detail>
      <Keyword>Ribonuclease H activity</Keyword>
      <Ontology_ID>GO:0004523</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a lipid.</Detail>
      <Keyword>Lipid binding</Keyword>
      <Ontology_ID>GO:0008289</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any nucleic acid.</Detail>
      <Keyword>Nucleic acid binding</Keyword>
      <Ontology_ID>GO:0003676</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1); the synthesis of DNA from deoxyribonucleotide triphosphates in the presence of a DNA template and primer.</Detail>
      <Keyword>DNA-directed DNA polymerase activity</Keyword>
      <Ontology_ID>GO:0003887</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Viral protein necessary for the penetration of the viral genome into the host cell nucleus either via active nuclear transport through nuclear pore complexes (NPCs) or DNA injection through the nuclear membrane. Nuclear membrane permeabilization might also be possible. Viruses can also enter the nucleus during mitosis when the nuclear membrane temporarily disintegrates (e.g. most retroviruses). All these strategies to cross the nuclear envelope barrier are associated with various levels of capsid disassembly, since virus can pass intact (e.g. papovaviruses) or, in the case of injection, only the viral genome enters the nucleus (e.g. herpesviruses).</Detail>
      <Keyword>Viral penetration into host nucleus</Keyword>
      <Ontology_ID>KW-1163</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Viral protein involved in the virion's initiation of infection into a host cell, including internalization and penetration into the host cell cytoplasm, intracellular transport of viral components and genome release to the replication site of the virus.</Detail>
      <Keyword>Initiation of viral infection</Keyword>
      <Ontology_ID>KW-1160</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a segment of DNA is incorporated into another, usually larger, DNA molecule such as a chromosome.</Detail>
      <Keyword>DNA integration</Keyword>
      <Ontology_ID>GO:0015074</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a virion enters a host cell, including virion attachment and penetration.</Detail>
      <Keyword>Entry of virus into host cell</Keyword>
      <Ontology_ID>GO:0046718</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which a new genotype is formed by reassortment of genes resulting in gene combinations different from those that were present in the parents. In eukaryotes genetic recombination can occur by chromosome assortment, intrachromosomal recombination, or nonreciprocal interchromosomal recombination. Intrachromosomal recombination occurs by crossing over. In bacteria it may occur by genetic transformation, conjugation, transduction, or F-duction.</Detail>
      <Keyword>DNA recombination</Keyword>
      <Ontology_ID>GO:0006310</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The period of virion development during which the capsid components form the immature capsid and encapsulate the viral genome; the capsid often undergoes a number of structural alterations during this period.</Detail>
      <Keyword>Viral procapsid maturation</Keyword>
      <Ontology_ID>GO:0046797</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Viral protein involved in the modulation of host cell apoptosis by acting different steps of the process. Several viruses encode proteins that inhibit apoptosis while other viruses use apoptosis to their advantage to suppress immune response or to disseminate.</Detail>
      <Keyword>Modulation of host cell apoptosis by virus</Keyword>
      <Ontology_ID>KW-1119</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a virus becomes free of a host cell either by the lysis of the host cell or by a non-lytic mechanism.</Detail>
      <Keyword>Release of virus from host</Keyword>
      <Ontology_ID>GO:0019076</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which an organism has an effect on an organism of a different species.</Detail>
      <Keyword>Interspecies interaction between organisms</Keyword>
      <Ontology_ID>GO:0044419</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Molecular events that lead to the integration of a viral genome into the host chromosomal DNA. Integrated viral DNA is referred to as a provirus (also called prophage in the case of bacterial viruses). A provirus does not necessarily make new DNA copies of itself while integrated into a host genome in this way. Instead, it can remain latent and be passively replicated along with the host genome and passed on to the original cell's offspring; all descendants of the infected cell will also bear proviruses in their genomes. The host's environmental conditions changes can however reactivate the provirus leading to viral transcription and production of new infectious viruses (productive infection). Integration occurs in retroviruses, some phages, phycodnaviruses, Adeno-associated virus type 2, and Human herpesvirus 6A.</Detail>
      <Keyword>Provirus integration</Keyword>
      <Ontology_ID>KW-1179</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Viral protein involved in the activation of host cell apoptosis by acting on host caspases. While many viruses encode protein that inhibit apoptosis, viruses can also use apoptosis to their advantage to suppress immune response or to disseminate. Therefore, some viral proteins are able to cleave or activate caspases in order to promote apoptosis.</Detail>
      <Keyword>Activation of host caspases by virus</Keyword>
      <Ontology_ID>KW-1073</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>132</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MGARASVLSGGKLDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQTGSEECRSLYNTVATLYCVHQRIEIKDTKEALDKIKEEQNKSKKKAQQAAADTGHSSQVSQNYPIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHIARNCRAPRKKGCWKCGKEGHQMKDCTERQANFFREDLAFLQGKAREFSSEQTRANSPTRRELQVWGRDNNSPSEAGADRQGTVSFNFPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGTHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKILFLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTSATVKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED</Protein_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Host cell endosome</CellLocal>
      <Ontology_ID>GO:0044174</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Host endosome</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Intracellular</CellLocal>
      <Ontology_ID>GO:0005622</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Virion membrane</CellLocal>
      <Ontology_ID>GO:0055036</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Viral capsid</CellLocal>
      <Ontology_ID>GO:0019028</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Host multivesicular body</CellLocal>
      <Ontology_ID>GO:0072494</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Host cytoplasm</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Host cell plasma membrane</CellLocal>
      <Ontology_ID>GO:0020002</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Host cell membrane</CellLocal>
      <Ontology_ID>GO:0033644</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Host cell cytoplasm</CellLocal>
      <Ontology_ID>GO:0030430</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Virion</CellLocal>
      <Ontology_ID>GO:0019012</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Host nucleus</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Host cell nucleus</CellLocal>
      <Ontology_ID>GO:0042025</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Viral nucleocapsid</CellLocal>
      <Ontology_ID>GO:0019013</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>gag-pol</Gene_Name>
  </Gene>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of wild type HIV-1 protease in complex with non-peptidic inhibitor, GRL007</PDB_Title>
      <PDB_ID>4I8W</PDB_ID>
      <Resolution>1.96</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I8W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel non-peptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.</PubMed_Title>
      <Author>Yedidi, R.S., et al.</Author>
      <Journal>Antimicrob.Agents Chemother.(2013)57:4920-4927</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/23877703?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of HIV-1 Reverse Transcriptase (RT) in complex with TSAO-T, a non-nucleoside RT inhibitor (NNRTI)</PDB_Title>
      <PDB_ID>3QO9</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QO9</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920056</ASD_Ligand>
      <PubMed_Title>Crystal Structure of tert-Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket.</PubMed_Title>
      <Author>Das, K., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:2727-2737</Journal>
      <PubMed_ID>21446702</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of HIV-1 Reverse Transcriptase (RT) in complex with a Difluoromethylbenzoxazole (DFMB) Pyrimidine Thioether derivative, a non-nucleoside RT inhibitor (NNRTI)</PDB_Title>
      <PDB_ID>2YKM</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2YKM</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920047</ASD_Ligand>
      <PubMed_Title>Difluoromethylbenzoxazole Pyrimidine Thioether Derivatives: A Novel Class of Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.</PubMed_Title>
      <Author>Boyer, J., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:7974</Journal>
      <PubMed_ID>22017513</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of HIV-1 reverse transcriptase in complex with gap-RNA/DNA and Nevirapine</PDB_Title>
      <PDB_ID>4Q0B</PDB_ID>
      <Resolution>3.3</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4Q0B</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02560019</ASD_Ligand>
      <PubMed_Title>Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage.</PubMed_Title>
      <Author>Das, K., et al.</Author>
      <Journal>Nucleic Acids Res.(2014)42:8125-8137</Journal>
      <PubMed_ID>24880687</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIV protease in complex with SA525P</PDB_Title>
      <PDB_ID>4MC2</PDB_ID>
      <Resolution>1.56</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4MC2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Optimization of Cyclic Sulfonamide based Novel HIV-1 Protease Inhibitors to Pico Molar Affinities guided by X-ray Crystallographic Analysis</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>HIV protease in complex with SA499</PDB_Title>
      <PDB_ID>4MC6</PDB_ID>
      <Resolution>1.31</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4MC6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Optimization of Cyclic Sulfonamide based Novel HIV-1 Protease Inhibitors to Pico Molar Affinities guided by X-ray Crystallographic Analysis</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-3-(3-bromo-5-(4-chloro-2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ518), a non-nucleoside inhibitor</PDB_Title>
      <PDB_ID>4LSN</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4LSN</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920066</ASD_Ligand>
      <PubMed_Title>Structure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse Transcriptase.</PubMed_Title>
      <Author>Frey, K.M., et al.</Author>
      <Journal>Chem.Biol.Drug Des.(2014)83:541-549</Journal>
      <PubMed_ID>24289305</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH an anilinylpyrimidine derivative (JLJ-135)</PDB_Title>
      <PDB_ID>4KO0</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4KO0</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920064</ASD_Ligand>
      <PubMed_Title>Extension into the entrance channel of HIV-1 reverse transcriptase-Crystallography and enhanced solubility.</PubMed_Title>
      <Author>Bollini, M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2013)23:5209-5212</Journal>
      <PubMed_ID>23899617</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN IMMUNODEFICIENCY VIRUS TYPE 1</PDB_Title>
      <PDB_ID>1HQU</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HQU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920019</ASD_Ligand>
      <PubMed_Title>The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.</PubMed_Title>
      <Author>Hsiou, Y., et al.</Author>
      <Journal>J.Mol.Biol.(2001)309:437-445</Journal>
      <PubMed_ID>11371163</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Apo HIV Protease (PR) dimer in closed form with fragment 1F1-N in the outside/top of flap</PDB_Title>
      <PDB_ID>4EJL</PDB_ID>
      <Resolution>2.44</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4EJL</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920002</ASD_Ligand>
      <PubMed_Title>Small molecule regulation of protein conformation by binding in the Flap of HIV protease.</PubMed_Title>
      <Author>Tiefenbrunn, T., et al.</Author>
      <Journal>Acs Chem.Biol.(2013)8:1223-1231</Journal>
      <PubMed_ID>23540839</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIV-1 reverse transcriptase with bound fragment at NNRTI adjacent site</PDB_Title>
      <PDB_ID>4KFB</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4KFB</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02560066;ASD11920014</ASD_Ligand>
      <PubMed_Title>Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-Ray Crystallographic Fragment Screening.</PubMed_Title>
      <Author>Bauman, J.D., et al.</Author>
      <Journal>J.Med.Chem.(2013)56:2738</Journal>
      <PubMed_ID>23342998</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TL-3 inhibited Trp6Ala HIV Protease with 3-bromo-2,6-dimethoxybenzoic acid bound in flap site</PDB_Title>
      <PDB_ID>4K4Q</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4K4Q</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01470057</ASD_Ligand>
      <PubMed_Title>Crystallographic Fragment-Based Drug Discovery: Use of a Brominated Fragment Library Targeting HIV Protease.</PubMed_Title>
      <Author>Tiefenbrunn, T., et al.</Author>
      <Journal>Chem.Biol.Drug Des.(2014)83:141-148</Journal>
      <PubMed_ID>23998903</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN IMMUNODEFICIENCY VIRUS TYPE 1</PDB_Title>
      <PDB_ID>1HPZ</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HPZ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920024</ASD_Ligand>
      <PubMed_Title>The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.</PubMed_Title>
      <Author>Hsiou, Y., et al.</Author>
      <Journal>J.Mol.Biol.(2001)309:437-445</Journal>
      <PubMed_ID>11371163</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of HIV-1 protease variant G48T/L89M in complex with Saquinavir</PDB_Title>
      <PDB_ID>4QGI</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4QGI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Defective Hydrophobic Sliding Mechanism and Active Site Expansion in HIV-1 Protease Drug Resistant Variant Gly48Thr/Leu89Met: Mechanisms for the Loss of Saquinavir Binding Potency.</PubMed_Title>
      <Author>Goldfarb, N.E., et al.</Author>
      <Journal>Biochemistry(2015)54:422-433</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/25513833?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of wild type HIV-1 protease in complex with non-peptidic inhibitor, GRL008</PDB_Title>
      <PDB_ID>4I8Z</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I8Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel non-peptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.</PubMed_Title>
      <Author>Yedidi, R.S., et al.</Author>
      <Journal>Antimicrob.Agents Chemother.(2013)57:4920-4927</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/23877703?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIV protease in complex with SA526P</PDB_Title>
      <PDB_ID>4MC1</PDB_ID>
      <Resolution>1.39</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4MC1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Optimization of Cyclic Sulfonamide based Novel HIV-1 Protease Inhibitors to Pico Molar Affinities guided by X-ray Crystallographic Analysis</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 4-((4-methoxy-6-(2-morpholinoethoxy)-1,3,5-triazin-2-yl)amino)-2-((3-methylbut-2-en-1-yl)oxy)benzonitrile (JLJ513), a non-nucleoside inhibitor</PDB_Title>
      <PDB_ID>4KKO</PDB_ID>
      <Resolution>2.89</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4KKO</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920063</ASD_Ligand>
      <PubMed_Title>Extension into the entrance channel of HIV-1 reverse transcriptase-Crystallography and enhanced solubility.</PubMed_Title>
      <Author>Bollini, M., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2013)23:5209-5212</Journal>
      <PubMed_ID>23899617</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of HIV-1 Reverse Transcriptase in complex with 4-((4-(mesitylamino)-6-(3-morpholinopropoxy)-1,3,5-triazin-2-yl)amino)benzonitrile (JLJ529), a non-nucleoside inhibitor</PDB_Title>
      <PDB_ID>4O44</PDB_ID>
      <Resolution>2.89</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4O44</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920068</ASD_Ligand>
      <PubMed_Title>A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase.</PubMed_Title>
      <Author>Mislak, A.C., et al.</Author>
      <Journal>Biochim.Biophys.Acta(2014)1840:2203-2211</Journal>
      <PubMed_ID>24726448</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIV Protease (PR) dimer in closed form with pepstatin in active site and fragment 1F1 in the outside/top of flap</PDB_Title>
      <PDB_ID>4EJD</PDB_ID>
      <Resolution>1.1</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4EJD</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920004</ASD_Ligand>
      <PubMed_Title>Small molecule regulation of protein conformation by binding in the Flap of HIV protease.</PubMed_Title>
      <Author>Tiefenbrunn, T., et al.</Author>
      <Journal>Acs Chem.Biol.(2013)8:1223-1231</Journal>
      <PubMed_ID>23540839</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of HIV-1 reverse transcriptase in complex with bulge-RNA/DNA and Nevirapine</PDB_Title>
      <PDB_ID>4PWD</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4PWD</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02560019</ASD_Ligand>
      <PubMed_Title>Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage.</PubMed_Title>
      <Author>Das, K., et al.</Author>
      <Journal>Nucleic Acids Res.(2014)42:8125-8137</Journal>
      <PubMed_ID>24880687</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-3-(3-chloro-5-(4-chloro-2-(2-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ494), a Non-nucleoside Inhibitor</PDB_Title>
      <PDB_ID>4H4M</PDB_ID>
      <Resolution>2.85</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4H4M</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02560102</ASD_Ligand>
      <PubMed_Title>Crystal Structures of HIV-1 Reverse Transcriptase with Picomolar Inhibitors Reveal Key Interactions for Drug Design.</PubMed_Title>
      <Author>Frey, K.M., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2012)134:19501-19503</Journal>
      <PubMed_ID>23163887</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of HIV-1 Reverse Transcriptase in Complex with 8-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)indolizine-2-carbonitrile (JLJ555), a non-nucleoside inhibitor</PDB_Title>
      <PDB_ID>4MFB</PDB_ID>
      <Resolution>2.88</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4MFB</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920067</ASD_Ligand>
      <PubMed_Title>Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl Group.</PubMed_Title>
      <Author>Lee, W.G., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2013)135:16705-16713</Journal>
      <PubMed_ID>24151856</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIV-1 Reverse Transcriptase in Complex with Manicol at the RNase H Active Site and TMC278 (Rilpivirine) at the NNRTI Binding Pocket</PDB_Title>
      <PDB_ID>3QLH</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QLH</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02560066</ASD_Ligand>
      <PubMed_Title>Synthesis, activity, and structural analysis of novel alpha-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H.</PubMed_Title>
      <Author>Chung, S., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:4462-4473</Journal>
      <PubMed_ID>21568335</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of HIV-1 reverse transcriptase in complex with rilpivirine (TMC278) based analogue</PDB_Title>
      <PDB_ID>4I2P</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I2P</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920061</ASD_Ligand>
      <PubMed_Title>A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.</PubMed_Title>
      <Author>Johnson, B.C., et al.</Author>
      <Journal>Retrovirology(2012)9:99-99</Journal>
      <PubMed_ID>23217210</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TL-3 inhibited Trp6Ala HIV Protease with 1-bromo-2-napthoic acid bound in exosite</PDB_Title>
      <PDB_ID>4K4R</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4K4R</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01470058</ASD_Ligand>
      <PubMed_Title>Crystallographic Fragment-Based Drug Discovery: Use of a Brominated Fragment Library Targeting HIV Protease.</PubMed_Title>
      <Author>Tiefenbrunn, T., et al.</Author>
      <Journal>Chem.Biol.Drug Des.(2014)83:141-148</Journal>
      <PubMed_ID>23998903</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIV Protease (PR) dimer in closed form with pepstatin in active site and fragment 1F1-N in the outside/top of flap</PDB_Title>
      <PDB_ID>4EJK</PDB_ID>
      <Resolution>1.79</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4EJK</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920002</ASD_Ligand>
      <PubMed_Title>Small molecule regulation of protein conformation by binding in the Flap of HIV protease.</PubMed_Title>
      <Author>Tiefenbrunn, T., et al.</Author>
      <Journal>Acs Chem.Biol.(2013)8:1223-1231</Journal>
      <PubMed_ID>23540839</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of HIV-1 Reverse Transcriptase (RT) in Complex with (E)-3-(3-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)- 4-fluorophenoxy)-5-fluorophenyl)acrylonitrile (JLJ506), A Non-nucleoside inhibitor</PDB_Title>
      <PDB_ID>4H4O</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4H4O</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02560175</ASD_Ligand>
      <PubMed_Title>Crystal Structures of HIV-1 Reverse Transcriptase with Picomolar Inhibitors Reveal Key Interactions for Drug Design.</PubMed_Title>
      <Author>Frey, K.M., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2012)134:19501-19503</Journal>
      <PubMed_ID>23163887</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of HIV-1 reverse transcriptase (RT) in complex with Rilpivirine (TMC278, Edurant), a non-nucleoside rt-inhibiting drug</PDB_Title>
      <PDB_ID>4G1Q</PDB_ID>
      <Resolution>1.51</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4G1Q</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02560066</ASD_Ligand>
      <PubMed_Title>Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase.</PubMed_Title>
      <Author>Kuroda, D.G., et al.</Author>
      <Journal>Nat Chem(2013)5:174-181</Journal>
      <PubMed_ID>23422558</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of HIV-1 reverse transcriptase in complex with RNA/DNA and Nevirapine</PDB_Title>
      <PDB_ID>4PUO</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4PUO</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02560019</ASD_Ligand>
      <PubMed_Title>Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage.</PubMed_Title>
      <Author>Das, K., et al.</Author>
      <Journal>Nucleic Acids Res.(2014)42:8125-8137</Journal>
      <PubMed_ID>24880687</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of HIV-1 reverse transcriptase (RT) with DNA and the nonnucleoside inhibitor nevirapine</PDB_Title>
      <PDB_ID>3V81</PDB_ID>
      <Resolution>2.85</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V81</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02560019</ASD_Ligand>
      <PubMed_Title>HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.</PubMed_Title>
      <Author>Das, K., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2012)19:253-259</Journal>
      <PubMed_ID>22266819</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of HIV-1 Protease Mutant V82A with novel P1'-Ligands GRL-02031</PDB_Title>
      <PDB_ID>3VFA</PDB_ID>
      <Resolution>1.43</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3VFA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.</PubMed_Title>
      <Author>Chang, Y.C., et al.</Author>
      <Journal>J.Med.Chem.(2012)55:3387-3397</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22401672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the HIV-1 Integrase catalytic domain with GSK1264</PDB_Title>
      <PDB_ID>4OJR</PDB_ID>
      <Resolution>1.82</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4OJR</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD05060022</ASD_Ligand>
      <PubMed_Title>Allosteric Inhibition of Human Immunodeficiency Virus Integrase: LATE BLOCK DURING VIRAL REPLICATION AND ABNORMAL MULTIMERIZATION INVOLVING SPECIFIC PROTEIN DOMAINS.</PubMed_Title>
      <Author>Gupta, K., et al.</Author>
      <Journal>J.Biol.Chem.(2014)289:20477-20488</Journal>
      <PubMed_ID>24904063</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of HIV-1 Reverse Transcriptase in Complex with (E)-3-(3-(4-chloro-2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (JLJ476), a non-nucleoside inhibitor</PDB_Title>
      <PDB_ID>4LSL</PDB_ID>
      <Resolution>2.69</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4LSL</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920065</ASD_Ligand>
      <PubMed_Title>Structure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse Transcriptase.</PubMed_Title>
      <Author>Frey, K.M., et al.</Author>
      <Journal>Chem.Biol.Drug Des.(2014)83:541-549</Journal>
      <PubMed_ID>24289305</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>p15 HIV RNaseH domain with inhibitor MK3</PDB_Title>
      <PDB_ID>3LP3</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LP3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors.</PubMed_Title>
      <Author>Su, H.P., et al.</Author>
      <Journal>J.Virol.(2010)84:7625-7633</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20484498?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIV Protease (PR) dimer in closed form with pepstatin in active site and fragment AK-2097 in the outside/top of flap</PDB_Title>
      <PDB_ID>4TVG</PDB_ID>
      <Resolution>2.18</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4TVG</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920074</ASD_Ligand>
      <PubMed_Title>Distinguishing Binders from False Positives by Free Energy Calculations: Fragment Screening Against the Flap Site of HIV Protease.</PubMed_Title>
      <Author>Deng, N., et al.</Author>
      <Journal>J.Phys.Chem.B(2015)119:976-988</Journal>
      <PubMed_ID>25189630</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIV protease in complex with AA74</PDB_Title>
      <PDB_ID>4MC9</PDB_ID>
      <Resolution>1.19</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4MC9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Optimization of Cyclic Sulfonamide based Novel HIV-1 Protease Inhibitors to Pico Molar Affinities guided by X-ray Crystallographic Analysis</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of HIV-1 Protease Mutant Q7K V32I L63I with a cyclic sulfonamide inhibitor</PDB_Title>
      <PDB_ID>3TH9</PDB_ID>
      <Resolution>1.34</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TH9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, Synthesis, and X-ray Crystallographic Analysis of a Novel Class of HIV-1 Protease Inhibitors.</PubMed_Title>
      <Author>Ganguly, A.K., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:7176-7183</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21916489?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HIV-1 REVERSE TRANSCRIPTASE (RT) IN COMPLEX WITH A DIFLUOROMETHYLBENZOXAZOLE (DFMB) PYRIMIDINE THIOETHER DERIVATIVE, A NON-NUCLEOSIDE RT INHIBITOR (NNRTI)</PDB_Title>
      <PDB_ID>2YKN</PDB_ID>
      <Resolution>2.12</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2YKN</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920047</ASD_Ligand>
      <PubMed_Title>Difluoromethylbenzoxazole Pyrimidine Thioether Derivatives: A Novel Class of Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.</PubMed_Title>
      <Author>Boyer, J., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:7974</Journal>
      <PubMed_ID>22017513</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of K103N/Y181C mutant of HIV-1 reverse transcriptase in complex with rilpivirine (TMC278) analogue</PDB_Title>
      <PDB_ID>4I2Q</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I2Q</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02562101</ASD_Ligand>
      <PubMed_Title>A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.</PubMed_Title>
      <Author>Johnson, B.C., et al.</Author>
      <Journal>Retrovirology(2012)9:99-99</Journal>
      <PubMed_ID>23217210</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIV integrase in complex with inhibitor</PDB_Title>
      <PDB_ID>4NYF</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4NYF</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920001</ASD_Ligand>
      <PubMed_Title>Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.</PubMed_Title>
      <Author>Fader, L.D., et al.</Author>
      <Journal>ACS Med Chem Lett(2014)5:422-427</Journal>
      <PubMed_ID>24900852</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Apo HIV Protease (PR) dimer in closed form with fragment 1F1 in the outside/top of flap</PDB_Title>
      <PDB_ID>4EJ8</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4EJ8</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11920004</ASD_Ligand>
      <PubMed_Title>Small molecule regulation of protein conformation by binding in the Flap of HIV protease.</PubMed_Title>
      <Author>Tiefenbrunn, T., et al.</Author>
      <Journal>Acs Chem.Biol.(2013)8:1223-1231</Journal>
      <PubMed_ID>23540839</PubMed_ID>
    </PDB>
  </PDB_List>
  <Fold>
    <CATH_Class>Class 3: Mixed Alpha-Beta </CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/3lp3</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <PDB_ID>4NYF</PDB_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD01470057</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01470058</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560059</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560063</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560064</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560066</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560073</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560102</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560169</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02560175</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02562083</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02562101</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05060022</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920021</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920022</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920024</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920028</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920029</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920030</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920032</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920034</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920037</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920039</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920040</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920041</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920044</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920045</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920046</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920047</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920053</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920054</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920056</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920061</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920063</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920064</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920065</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920066</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920067</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920068</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920073</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11920074</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2015-04-08</Create_Date>
</Organism_Record>